Compare Symbotic Inc (SYM) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Symbotic Inc vs BIO-TECHNE Corp — how do they compare? Symbotic Inc trades at $43.04 (market cap $5.19B), while BIO-TECHNE Corp trades at $71.63 (market cap $11.16B). The key difference: BIO-TECHNE Corp is far larger — about 2.2× Symbotic Inc's market cap, and BIO-TECHNE Corp pays a 0.45% dividend while Symbotic Inc pays none. Which is the better fit depends on your goals.
| SYM | TECH | |
|---|---|---|
Market Cap | $5.19B | $11.16B |
Sector | Technology | Health |
52-Week High | $87.30 | $72.12 |
52-Week Low | $38.57 | $43.31 |
Enterprise Value | $3.18B | $11.24B |
Dividend Yield | — | 0.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Symbotic (SYM) trades at $40.83, down 1.02% recently, with a bearish technical signal and key support at $40. The company reported revenue of $2.25 billion in 2025 but a net loss of $16.94 million, though gross margins improved to 20.43%. Recent news highlights its acquisition of ARMS Innovations and upcoming Q3 2026 earnings on August 5, 2026, amid growing interest in warehouse automation.
Analyst consensus is bullish with a $57.50 price target, but risks include persistent net losses, high EV/EBITDA of 219.3, and competitive pressures. The stock offers growth potential from AI-driven warehouse automation demand, yet profitability challenges and market volatility pose significant headwinds for investors.
Bio-Techne (TECH) trades at $71.64, down 0.67% today, near its 52-week high following Merck KGaA's $73 per share acquisition offer. The stock shows bullish technical signals with strong moving averages, though RSI indicates overbought conditions. Recent earnings have been mixed, with Q4 2025 beating expectations but Q1 2026 missing. The company maintains solid gross margins of 64.96% but faces declining net income margins, down to 6.01% in 2025 from 25.09% in 2023.
The outlook is heavily influenced by the pending acquisition, offering a clear exit near current levels. Risks include shareholder litigation over deal fairness and fundamental profitability pressures. With a high P/E of 103.03, the stock's upside appears capped without the deal, while the $73 bid provides a near-term floor. Investors should weigh acquisition completion probability against operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Symbotic Inc
Symbotic is an automation technology leader that provides an end-to-end, A.I.-powered robotic platform for large-scale warehouse operations. By utilizing untethered, high-speed autonomous bots and sophisticated vision systems, Symbotic transforms traditional distribution centers into high-density strategic assets. The company serves the world’s largest retailers and wholesalers—most notably Walmart—while expanding into 'Warehouse-as-a-Service' through its GreenBox joint venture to democratize advanced automation for smaller enterprises.
Read more on SYM →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
